Study of CTX112 for adults with autoimmune disease
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 69 years old.
- You have been diagnosed with lupus, scleroderma, or inflammatory myositis by a specialist.
- Your heart, lungs, kidneys, liver, and blood counts are working well enough.
- You have not had a previous treatment targeting CD19 or any gene/cell therapy before.
- You do not have an active serious infection or cancer in the last 5 years (except low-risk cancers).
- You are not pregnant or breastfeeding and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
This study is testing an experimental medicine called PF-08154225 to see if it can help treat several autoimmune conditions, including rheumatoid arthritis, lupus, and related disorders. It might reduce disease activity or symptoms in people who have not found relief from other treatments.
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
This study tests a new treatment called CTX112, which uses modified immune cells to target and calm the immune system. It is for people with certain autoimmune diseases that have not responded to other treatments.
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
Hear when a new SLE (Systemic Lupus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.